Optimization of pyrazolopyridine 4-carboxamides with potent antimalarial activity for which resistance is associated with the P. falciparum transporter ABCI3

Published in: European Journal of Medicinal Chemistry, Volume 276, 5 October 2024, 116677

DOI: 10.1016/j.ejmech.2024.116677

Authors: Petar P.S. Calic, Trent D. Ashton, Mahta Mansouri, Katie Loi, KateE. Jarman, Deyun Qiu, Adele M. Lehane, Sayantan Roy [TCGLS Member], Gunturu P. Rao [TCGLS Member], Bikash Maity [TCGLS Member], Sergio Wittlin, Benigno Crespo, Franciso-Javier Gamo, Ioanna Deni, David A. Fidock, Mrittika Chowdury, Tania F. de Koning-Ward, Alan F. Cowman, Paul F. Jackson, Delphine Baud,  Stephen Brand, Benoît Laleu, Brad E. Sleebs

Abstract: Emerging resistance to current antimalarials is reducing their effectiveness and therefore there is a need to develop new antimalarial therapies. Toward this goal, high throughput screens against the P. falciparum asexual parasite identified the pyrazolopyridine 4-carboxamide scaffold. Structure-activity relationship analysis of this chemotype defined that the N1-tert-butyl group and aliphatic foliage in the 3- and 6-positions were necessary for activity, while the inclusion of a 7′-aza-benzomorpholine on the 4-carboxamide motif resulted in potent anti-parasitic activity and increased aqueous solubility. A previous report that resistance to the pyrazolopyridine class is associated with the ABCI3 transporter was confirmed, with pyrazolopyridine 4-carboxamides showing an increase in potency against parasites when the ABCI3 transporter was knocked down. The low metabolic stability intrinsic to the pyrazolopyridine scaffold and the slow rate by which the compounds kill asexual parasites resulted in poor performance in a P. berghei asexual blood stage mouse model. Lowering the risk of resistance and mitigating the metabolic stability and cytochrome P450 inhibition will be challenges in the future development of the pyrazolopyrimidine antimalarial class.

Graphical Abstract